Richard Roxburgh - Concepedia

Author

Richard Roxburgh

Also Known As

Annemare Ranta, Jennifer Faber, Paula R. Clemens, R Roxburgh, R. H. Roxburgh, R. H. S. R. Roxburgh, R. H.S.R. Roxburgh, R. Roxburgh, R.H. Roxburgh, Richard H Roxburgh

175

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Auckland City Hospital University of Auckland Auckland District Health Board University of Cambridge University of Calgary

About

Richard Roxburgh is an author at Auckland City Hospital specializing in medicine, neurology, and neuropathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	26	2.2K
2	Public Health	5	5	353
3	Engineering	4	4	891
4	Health Sciences	3	3	232
5	Arts	1	1	23

Richard Roxburgh

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Multiple Sclerosis Severity Score Richard Roxburgh, Shaun R. Seaman, Thomas Masterman, Neurology	2005	945
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations Catherine L. Bladen, David Salgado, Soledad Monges, Human Mutation Dmd MutationsTrial PlanningEngineeringMendelian DisorderGenetic Disorder	2015	717
Cerebellar ataxia, neuropathy, vestibular areflexia syndrome due to RFC1 repeat expansion Andrea Cortese, Stefano Tozza, Wai Yan Yau, Brain Vestibular Areflexia SyndromeMotor DysfunctionNeurological DisorderCorticobasal DegenerationPathology	2020	213
Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database Zaïda Koeks, Catherine L. Bladen, David Salgado, Journal of Neuromuscular Diseases	2017	171
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial Benedikt Schoser, Mark Roberts, Barry J. Byrne, The Lancet Neurology Clinical TrialsCipaglucosidase AlfaPharmacotherapyMedicineLate-onset Pompe Disease	2021	124
A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility Stephen Sawcer, Mel Maranian, Efrosini Setakis, Brain	2002	114
Haplotypes and gene expression implicate the <i>MAPT</i> region for Parkinson disease Jennifer E. Tobin, Jeanne C. Latourelle, Mark Lew, Neurology	2008	110
The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study Jeanne C. Latourelle, Mei Sun, Mark Lew, BMC Medicine	2008	107
A retrospective study of the impact of lifestyle on age at onset of Huntington disease M. Kaye Trembath, Z. Horton, Lynette J. Tippett, Movement Disorders AgingLifestyle PassivityEpidemiology Of AgingLifestyle Passivity ScoresHealthy Aging	2010	105
The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia Catherine L. Bladen, Karen Rafferty, Volker Straub, Human Mutation Rare DiseasesDmd RegistriesDuchenne Muscular DystrophyPrecision MedicineClinical Trials	2013	103

Page 1